Previous 10 | Next 10 |
Catalyst Pharmaceuticals (NASDAQ: CPRX ) discloses that it has settled a patent dispute with Northwestern University related to pipeline candidate CPP-115. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
For the past several months, Florida-based Catalyst Pharmaceuticals (NASDAQ: CPRX ) has taken its investors on a bumpy ride. After Catalyst received approval for its lead drug candidate Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in November 2018, the stock pric...
Gainers : PDS Biotechnology (NASDAQ: PDSB ) +35% . Navios Maritime Holdings (NYSE: NM ) +26% . Cellectar Biosciences (NASDAQ: CLRB ) +21% . Nordic American Tankers (NYSE: NAT ) +14% . Ocean Bio-Chem (NASDAQ: OBCI ) +13% . Genetic Technologies (NASDAQ: GENE ) +13% . Amdocs (NASDAQ: DO...
NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) , a company focused on developing ...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. The Bounce/Lag...
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2019 Earnings Conference Call May 13, 2019 8:30 AM Company Participants Alicia Grande – Chief Financial Officer Pat McEnany – Chairman and Chief Executive Officer Dan Brennan – Chief Commercial Officer Steve Miller &...
Amber Road (NYSE: AMBR ) +26% on being acquired by E2open. More news on: Amber Road, Inc., Onconova Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., Stocks on the move, Read more ...
Catalyst Pharmaceuticals ( CPRX ) Q1 results : Revenues: $12.4M. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q1 GAAP EPS of -$0.01 beats by $0.07 . More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse -Company to Host Quarterly Conference Call at 8:30 am ET Today CORAL GABLES, Fla., May 13,...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...